Human Organoids Market worth $1,901 million by 2025 – Exclusive Report by MarketsandMarkets™

PUNE, India, 2021-Nov-25 — /EPR Network/ —

According to the new market research report, “Human Organoids Market by Product (Pancreas, Kidney, Lung, GIT, Liver Models) Usabilty (Customized, Ready-To-Use), Application (Toxicity, Pathology, Personalized & Regenerative Medicine), Enduser (Pharma-Biotech, CROs, Academia) & Region- Global Forecast to 2025″, The global human organoids market size is estimated to be USD 850 million in 2020 and projected to reach USD 1,901 million by 2025, at a CAGR of 17.5 %.

Browse and in-depth TOC on “Human Organoids Market”
143 – Tables
23 – Figures
174 – Pages

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=171046468

Growth Boosting Factors:

Increasing prevalence of transplantation, technological advancements and increased funding and public-private investments are the key factors driving the growth of the human organoids.

The human organoids market includes major Tier I and II suppliers like BioIVT (US), Thermo Fisher Scientific (US), ZenBio (US), Corning (US), Organovo (US), Cyprio (France), Biopredic International (France), CELLINK (Sweden), Emulate (US), Hµrel Corporation (US), InSphero (Switzerland), Kerafast (US), Kirkstall (UK), and MIMETAS (Netherlands). These suppliers have their manufacturing facilities spread across regions such as North America and Europe. COVID-19 has impacted their businesses as well. Demand for human organoids from key end-users has declined  a bit amidst the global COVID-19 pandemic. Industry experts believe that COVID-19 will have short-term decline in the growth for the human organoids market in 2020, but will experience normal growth as the market gradually steadies by the end of 2020.

Demand for liver transplants result in the segment occupying the high share of the human orgnaoids market

Liver segment owes a good market share in Human Orgnaoids market. The large share of this segment is attributed to factors such as the advancements in technology among researchers and academia (coupled with growing industry-academia collaborations for organoids research, rising numbers of liver transplants and the investments by the both private and public players in the market.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=171046468

Kidney estimated to be the growing market

The kidney human orgnaoids market is expected to witness sustained demand during the forecast period, owing to the high prevalence of infectious diseases across major markets (resulting in a growing number of transplant procedures),  and an increasing number of life science researches in the field of specific requirements and treatment, especially across emerging countries.

Asia Pacific likely to emerge as the fastest growing clinical microbiology market, globally

Geographically, the emerging Asian countries, such as China, India, South Korea, Taiwan, and Singapore, are offering high-growth opportunities for market players. The Asia Pacific clinical microbiology market is projected to grow at the highest CAGR of 18.8% from 2020 to 2025. Government efforts to increase awareness related to human organoids; supportive regulations for the development and commercialization of advanced human orgnaoids products; rising healthcare expenditure; the increasing number of hospitals in India and China; expanding research base across India, China, and Japan; and the increasing incidence of transpalnts are driving the growth of the APAC clinical microbiology market.

Prominent players in this market BioIVT (US), Thermo Fisher Scientific (US), ZenBio (US), Corning (US), Organovo (US), Cyprio (France), Biopredic International (France), CELLINK (Sweden), Emulate (US), Hµrel Corporation (US), InSphero (Switzerland), Kerafast (US), Kirkstall (UK), and MIMETAS (Netherlands).

Speak to Analyst@ https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=171046468

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledgestore” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: 1-888-600-6441
Email: sales@marketsandmarkets.com
Content Source: https://www.marketsandmarkets.com/PressReleases/human-liver-model.asp
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/human-liver-model-market.asp

Matched content

Editor’s pick

Express Press Release Distribution